National Cancer Institute Thesaurus

Last uploaded: February 23, 2024
Preferred Name

Thalidomide

Synonyms

Alpha-Phthalimidoglutarimide

thalidomide

Thalidomide

(-)-Thalidomide

Sedoval K17

Sedoval K-17

.alpha.-Phthalimidoglutarimide

THALIDOMIDE

2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione

N-Phthalylglutamic acid imide

N-(2,6-Dioxo-3-piperidyl)phthalimide

Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-

N-Phthalylglutamic Acid Imide

(+)-Thalidomide

3-Phthalimidoglutarimide

N-Phthaloylglutamimide

2, 6-Dioxo-3-phthalimidopiperidine

2,6-Dioxo-3-phthalimidopiperidine

Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-

Contergan

Distaval

Kevadon

Neurosedyn

Pantosediv

Sedalis

Softenon

Synovir

Talimol

Thalomid

Definitions

A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.

ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C870

Accepted_Therapeutic_Use_For

Aphthous stomatitis; Crohns disease; cutaneous manifestations of erythema nodosum leprosum; GVHD; HIV-associated wasting syndrome; Karposi sarcoma; lepromatous leprosy; multiple myeloma; mycobacterium tuberculosis and nontuberculosis; primary brain tumors

ALT_DEFINITION

A drug that is used to treat multiple myeloma in patients who have just been diagnosed, and a painful skin disease related to leprosy. It is also being studied in the treatment of other types of cancer. Thalomid belongs to the family of drugs called angiogenesis inhibitors.

CAS_Registry

50-35-1

CHEBI_ID

CHEBI:9513

Chemical_Formula

C13H10N2O4

code

C870

Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C177537

Contributing_Source

CTRP

FDA

GDC

HemOnc

DEFINITION

A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.

Display_Name

Thalidomide

FDA_UNII_Code

4Z8R6ORS6L

FULL_SYN

Alpha-Phthalimidoglutarimide

thalidomide

Thalidomide

(-)-Thalidomide

Sedoval K17

Sedoval K-17

.alpha.-Phthalimidoglutarimide

THALIDOMIDE

2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione

N-Phthalylglutamic acid imide

N-(2,6-Dioxo-3-piperidyl)phthalimide

Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (+)-

N-Phthalylglutamic Acid Imide

(+)-Thalidomide

3-Phthalimidoglutarimide

N-Phthaloylglutamimide

2, 6-Dioxo-3-phthalimidopiperidine

2,6-Dioxo-3-phthalimidopiperidine

Phthalimide, N-(2, 6-dioxo-3-piperidyl)-, (-)-

Contergan

Distaval

Kevadon

Neurosedyn

Pantosediv

Sedalis

Softenon

Synovir

Talimol

Thalomid

Has_Target

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C20450

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C20535

Is_Value_For_GDC_Property

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1909

label

Thalidomide

Legacy Concept Name

Thalidomide

Maps_To

Thalidomide

NCI_Drug_Dictionary_ID

42332

NSC Number

66847

PDQ_Closed_Trial_Search_ID

42332

PDQ_Open_Trial_Search_ID

42332

Preferred_Name

Thalidomide

prefixIRI

Thesaurus:C870

Semantic_Type

Organic Chemical

Pharmacologic Substance

UMLS_CUI

C0039736

subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1742

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C574

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157388

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C54677

Delete Subject Author Type Created
No notes to display
Create mapping

Delete Mapping To Ontology Source
http://www.phoc.org.cn/pmo/class/PMO_00016567 PMAPP-PMO LOOM
http://purl.bioontology.org/ontology/MESH/D013792 MESH LOOM
http://purl.bioontology.org/ontology/RXNORM/10432 RXNORM LOOM
http://purl.obolibrary.org/obo/OMIT_0014645 OMIT LOOM
http://purl.obolibrary.org/obo/NCIT_C870 BERO LOOM
http://purl.bioontology.org/ontology/NDDF/005933 NDDF LOOM
http://purl.bioontology.org/ontology/SNOMEDCT/78702007 SNOMEDCT LOOM
http://evs.nci.nih.gov/ftp1/NDF-RT/NDF-RT.owl#N0000148588 ODAE LOOM
http://purl.bioontology.org/ontology/PDQ/CDR0000042332 PDQ LOOM
http://purl.obolibrary.org/obo/CHEBI_74947 FIDEO LOOM
http://phenomebrowser.net/ontologies/mesh/mesh.owl#D02.241.223.805.810.800 RH-MESH LOOM
http://purl.obolibrary.org/obo/CHEBI_9513 EFO LOOM
http://purl.obolibrary.org/obo/CHEBI_9513 PDRO LOOM
http://purl.obolibrary.org/obo/CHEBI_9513 DISDRIV LOOM
http://purl.obolibrary.org/obo/CHEBI_9513 DINTO LOOM
http://purl.obolibrary.org/obo/CHEBI_9513 COVID-19 LOOM
http://purl.obolibrary.org/obo/CHEBI_9513 BERO LOOM
http://purl.obolibrary.org/obo/CHEBI_9513 BIOMODELS LOOM
http://purl.obolibrary.org/obo/CHEBI_9513 DRON LOOM
http://purl.obolibrary.org/obo/CHEBI_9513 CHEBI LOOM
http://purl.jp/bio/4/id/200906035965119250 IOBC LOOM
http://purl.obolibrary.org/obo/MESH_D013792 BERO LOOM
http://phenomebrowser.net/ontologies/mesh/mesh.owl#D03.383.621.808.800 RH-MESH LOOM
http://phenomebrowser.net/ontologies/mesh/mesh.owl#D03.438.513.750.750 RH-MESH LOOM
http://www.semanticweb.org/administrator/ontologies/2022/0/untitled-ontology-34#OWLClass08828d2b_184c_4083_b9f9_8e82ef976a51 WWECA LOOM
http://purl.bioontology.org/ontology/ATC/L04AX02 ATC LOOM
http://purl.obolibrary.org/obo/DRON_00015922 ODNAE LOOM
http://purl.bioontology.org/ontology/NDFRT/N0000148588 NDFRT LOOM
http://stirdf.jst.go.jp/id/200907009440214379 IOBC LOOM
http://www.drugbank.ca/drugs/DB01041 FTC LOOM
http://sbmi.uth.tmc.edu/ontology/ochv#12148 OCHV LOOM
http://ontology.apa.org/apaonto/termsonlyOUT%20(5).owl#Thalidomide APAONTO LOOM
https://go.drugbank.com/drugs/DB01041 MDM LOOM
http://www.projecthalo.com/aura#Thalidomide AURA LOOM
http://purl.bioontology.org/ontology/VANDF/4021134 VANDF LOOM
http://purl.bioontology.org/ontology/npo#NPO_434 NPO LOOM
http://purl.bioontology.org/ontology/SNMI/C-64085 SNMI LOOM
http://phenomebrowser.net/ontologies/mesh/mesh.owl#D013792 RH-MESH LOOM
http://purl.bioontology.org/ontology/CSP/0397-6187 CRISP LOOM
http://sbmi.uth.tmc.edu/ontology/ochv#C0039736 OCHV LOOM